<DOC>
	<DOC>NCT00909597</DOC>
	<brief_summary>This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial screening period, patients will be randomized to one of 3 groups, to receive a)taspoglutide 10mg sc weekly, b)taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly or c)pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po.The anticipated time on study treatment is 24 months, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes mellitus; treated with stable sulfonylurea monotherapy or metformin + sulfonylurea for &gt;=12 weeks prior to screening; HbA1c &gt;=7.0% and &lt;=10% at screening; stable weight +/5% for &gt;=12 weeks prior to screening. type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes; clinically significant diabetic complications; clinically symptomatic gastrointestinal disease; &gt;3 episodes of severe hypoglycemia within 6 months before screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>